AU2001230892A1 - Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same - Google Patents

Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same

Info

Publication number
AU2001230892A1
AU2001230892A1 AU2001230892A AU3089201A AU2001230892A1 AU 2001230892 A1 AU2001230892 A1 AU 2001230892A1 AU 2001230892 A AU2001230892 A AU 2001230892A AU 3089201 A AU3089201 A AU 3089201A AU 2001230892 A1 AU2001230892 A1 AU 2001230892A1
Authority
AU
Australia
Prior art keywords
preparing
same
pharmaceutical formulations
orally administered
benzimidazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230892A
Inventor
Shan-Chiung Chen
Hang-Chiang Kuo
Fang-Yu Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlsbad Technology Inc
Original Assignee
Carlsbad Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsbad Technology Inc filed Critical Carlsbad Technology Inc
Publication of AU2001230892A1 publication Critical patent/AU2001230892A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001230892A 2000-01-19 2001-01-11 Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same Abandoned AU2001230892A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09488406 2000-01-19
US09/488,406 US6228400B1 (en) 1999-09-28 2000-01-19 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
PCT/US2001/000817 WO2001052816A2 (en) 2000-01-19 2001-01-11 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same

Publications (1)

Publication Number Publication Date
AU2001230892A1 true AU2001230892A1 (en) 2001-07-31

Family

ID=23939604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230892A Abandoned AU2001230892A1 (en) 2000-01-19 2001-01-11 Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same

Country Status (8)

Country Link
US (1) US6228400B1 (en)
EP (1) EP1185254B1 (en)
JP (1) JP4293750B2 (en)
KR (1) KR100740218B1 (en)
CN (1) CN1212833C (en)
AU (1) AU2001230892A1 (en)
DE (1) DE60100186T2 (en)
WO (1) WO2001052816A2 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070231402A1 (en) 1994-08-02 2007-10-04 Immunopath Profile, Inc. Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR20030011797A (en) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 Granulated particles with masked taste
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
WO2002092092A1 (en) * 2001-05-15 2002-11-21 Taisho Pharmaceutical Co., Ltd. Minoxidil-containing liquid composition
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
KR100479637B1 (en) * 2002-02-01 2005-03-31 한국화학연구원 Oral dosage form comprising Lansoprazole and preparation method for the same
JP2005521712A (en) 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Solubilization of weak bases
EP1524967B1 (en) 2002-08-02 2008-03-12 Ratiopharm GmbH Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
DE10235475B4 (en) * 2002-08-02 2006-04-27 Ratiopharm Gmbh Medicaments containing a benzimidazole compound in admixture with microcrystalline cellulose and process for their preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
WO2004103338A1 (en) * 2003-05-19 2004-12-02 Bioprogress Plc Adhesives and film modifying compositions
WO2004112756A1 (en) * 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7312439B1 (en) 2003-08-18 2007-12-25 Rad Elec Inc. Radon progeny monitor
EP1686982A4 (en) * 2003-11-19 2007-03-21 Vecta Ltd Methods and compositions for the treatment of helicobacter pylori -associated diseases using endoperoxide bridge-containing compounds
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
JPWO2005084649A1 (en) * 2004-03-04 2007-11-29 武田薬品工業株式会社 Stable capsule
DE602005003343T2 (en) * 2004-04-12 2008-09-11 Pfizer Products Inc., Groton MEDICINAL PRODUCTS WITH HIDDEN TASTE IN BREAKING MULTIPARTICLES
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
KR100771426B1 (en) * 2006-02-03 2007-10-30 한국유나이티드제약 주식회사 Pharmaceutical composition using the micro-pellet and the preparation thereof
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
CH698658B1 (en) * 2006-04-24 2009-09-30 Mepha Ag An oral pharmaceutical formulation with rapid release for pyridylmethylsulfinyl-benzimidazoles.
WO2007125397A2 (en) * 2006-04-27 2007-11-08 Vecta, Ltd. Compositions and methods for inhibiting gastric acidity using endoperoxide bridge-containing compounds
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
RU2467747C2 (en) * 2006-07-25 2012-11-27 Векта Лтд. Compositions and methods for gastric acid secretion inhibition with using small dicarboxylic acid derivatives in combination with ppi
US9095512B2 (en) * 2006-08-11 2015-08-04 Asahi Kasei Chemicals Corporation Method for producing spherical base granules comprising hardly water-soluble drug
CA2667039A1 (en) * 2006-10-17 2008-04-24 Ranbaxy Laboratories Limited Multiple unit tablet compositions of benzimidazole compounds
US20080131563A1 (en) * 2006-11-30 2008-06-05 Vladek Kasperchik Food-compatible laser-imageable coatings
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
EP2091519B1 (en) * 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
CL2008002267A1 (en) * 2008-07-31 2009-07-03 Servicios Cientificos Neuroinnovation Ltda Use of compounds derived from pyrinmethylsulfinylbenzimadazole and piperidinylaminobenzimidazole as specific markers for neurodegenerative diseases and tau pathologies; and as a method of diagnosing Alzheimer's disease, and pharmaceutical formulation comprising said radiolabelled or fluorescently labeled compounds.
DE102008045339A1 (en) * 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmaceutical pellet
JP5661630B2 (en) * 2008-09-09 2015-01-28 シマ ラブス インク． Weak ionic compound dosage forms
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
MX2013000827A (en) * 2010-07-22 2013-06-28 Lupin Ltd Multiple unit tablet composition.
CN101953802B (en) * 2010-09-14 2012-05-09 陈敏伟 Lansoprazole enteric preparation and preparation method thereof
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
KR102060738B1 (en) * 2012-12-13 2019-12-30 한미약품 주식회사 Bitter taste masked pharmaceutical formulation comprising esomeprazole free base or alkali salt thereof and preparation method thereof
CN103386133A (en) * 2013-07-09 2013-11-13 重庆莱美药业股份有限公司 Oral instant preparation of proton pump inhibitor and preparation method thereof
WO2015057191A1 (en) 2013-10-15 2015-04-23 General Electric Company Methods and compositions for improving oil recovery in corn processing
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
UA120715C2 (en) * 2015-03-31 2020-01-27 Лабораторіос Баго С.А. Enteric-coated pellets containing a proton pump inhibitor
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
US9714398B2 (en) 2015-07-31 2017-07-25 General Electric Company Method for improving corn oil extraction using alkyl polyglycosides
US11286446B2 (en) 2016-02-18 2022-03-29 Bl Technologies, Inc. Stillage solids concentration
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy
KR102555956B1 (en) 2021-03-09 2023-07-18 주식회사한국파마 Immediate release oral formulation with enhenced stability comprising Rabeprazole and method for preparing the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JPH05194225A (en) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd Stabilized antiulcer agent-containing preparation
FR2692146B1 (en) 1992-06-16 1995-06-02 Ethypharm Sa Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.
JPH0733659A (en) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd Antiulcer agent-containing pharmaceutical preparation
EP0642797B1 (en) * 1993-09-09 2000-05-17 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
DE4439452A1 (en) * 1994-11-04 1996-05-09 Boehringer Mannheim Gmbh Antibody class-specific anti-interference reagent
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ES2137862B1 (en) * 1997-07-31 2000-09-16 Intexim S A ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING.

Also Published As

Publication number Publication date
JP2003520224A (en) 2003-07-02
DE60100186T2 (en) 2004-01-08
WO2001052816A3 (en) 2001-12-20
KR100740218B1 (en) 2007-07-18
CN1212833C (en) 2005-08-03
WO2001052816A2 (en) 2001-07-26
EP1185254B1 (en) 2003-04-16
EP1185254A2 (en) 2002-03-13
DE60100186D1 (en) 2003-05-22
CN1358089A (en) 2002-07-10
KR20010114225A (en) 2001-12-31
US6228400B1 (en) 2001-05-08
JP4293750B2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
AU762322C (en) Novel galenic formulations of meloxicam for oral administration
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
EE9900441A (en) Pharmaceutical composition for oral administration of the N-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates
AU2001235691A1 (en) Use of paullone derivatives for making medicines
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
AU2177001A (en) Use of indirubine derivatives for making medicines
HUP0301075A3 (en) Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds
AU2001287977A1 (en) Controlled release formulations for oral administration
AU2001284444A1 (en) Preparations for oral administration
NO20014738L (en) Tolperisone-containing pharmaceutical preparation for oral administration
AU6715600A (en) Pharmaceutical formulations
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU1354495A (en) Formulations for orally administered pharmaceutical agents
AU3913900A (en) Radioenhanced cancer treatment using orally administered camptothecin derivatives
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives
AU4977300A (en) Pharmaceutical formulations
AU1385801A (en) Pharmaceutical formulations
AU5241200A (en) Retard formulation of amoxicillin for oral administration